<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702855</url>
  </required_header>
  <id_info>
    <org_study_id>ARL/15/421</org_study_id>
    <nct_id>NCT03702855</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Dose, Crossover, Fully Replicated Oral Bioequivalence Study of Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited, India Comparing With XENAZINE® (Tetrabenazine) Tablets 25 mg of Lundbeck Inc., USA in Healthy, Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, four-period, two-treatment, two-sequence, balanced, single
      dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fed
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, four-period, two-sequence, single dose,
      crossover, fully replicated oral bioequivalence study of Tetrabenazine Tablets 25 mg of Dr.
      Reddy's Laboratories Limited, India comparing with XENAZINE® (tetrabenazine) Tablets 25 mg of
      Lundbeck Inc., USA in healthy, adult, human subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve</measure>
    <time_frame>Pre-dose (within 1 hour prior to dosing), 0.33, 0.67, 1.00, 1.33, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 24.00 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tetrabenazine Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xenazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xenazine Tablets 25 mg of Lundbeck Inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrabenazine Tablets 25 mg</intervention_name>
    <arm_group_label>Tetrabenazine Tablets</arm_group_label>
    <arm_group_label>Xenazine</arm_group_label>
    <other_name>Xenazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and non pregnant female human subjects, age in the range of 18-45 years both
             inclusive.

          2. Body mass index within the range of 18.5 kg/m2- 24.99 kg/m2 extremes included and body
             weight &gt; 50 kg.

          3. Subjects with normal findings as determined by baseline history, physical examination
             and vital signs examination (blood pressure, pulse rate, respiration rate and axillary
             temperature).

          4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry,
             urinalysis, 12 lead ECG.

          5. Willingness to follow the protocol requirements especially abstaining from xanthine
             containing food or beverages (chocolates, tea, coffee or cola drinks) or use of
             grapefruit juice, any alcoholic products, the use of cigarettes and tobacco products
             for 48.00 hours prior to dosing until after the last blood sample collection in each
             study period and adherence to food, fluid and posture restrictions.

          6. No history of significant alcoholism.

          7. No history of drug abuse (benzodiazepines and barbiturates) for the last one month and
             other illegal drugs for the last 6 months.

          8. Non-smokers, ex-smokers and moderate smokers were included. &quot;Moderate smokers are
             defined as someone smoking 10 cigarettes or less per day, ex-smokers are someone who
             completely stopped smoking for at least 3 months.&quot;

          9. Willing to use an acceptable, effective method of contraception.

         10. Subject must be literate, able to sign their name, and able to give voluntary written
             informed consent for the trial

         11. Able to read and understand the Informed Consent Form and Medication guide either in
             its original form (i.e. in English) or translated into a regional language

        Exclusion Criteria:

          1. Subject is illiterate.

          2. Subjects with a history of depression or prior suicide attempts or ideation

          3. Known history of hypersensitivity to Tetrabenazine or related drugs.

          4. Requiring medication for any ailment having enzyme-modifying activity in the previous
             28 days, prior to dosing day.

          5. Subjects who have taken prescription medications or over-the-counter products
             (including vitamins and minerals) within 14 days prior to administration of
             Investigational Product.

          6. Any medical or surgical conditions, which might significantly interfere with the
             functioning of gastrointestinal tract, blood-forming organs etc.

          7. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
             metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric
             diseases.

          8. Participation in a clinical drug study or bioequivalence study 90 days prior to
             Period-I dosing of the present study.

          9. History of malignancy or other serious diseases.

         10. Blood donation 90 days prior to period I dosing of the present study.

         11. Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.

         12. Found positive in urine test for drug abuse.

         13. History of problem in swallowing.

         14. Any contraindication to blood sampling.

         15. Found positive serum (β) Beta- hCG (Human Chorionic Gonadotropin) test.

         16. Lactating women (currently breast feeding).

         17. Female subjects not confirming to using birth control measures, from the date of
             screening until the completion of the study. Abstinence, barrier methods (condom,
             diaphragm, etc.) are acceptable.

         18. Use of hormonal contraceptives either oral or implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Vivekananda Murthi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Laboratories (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Laboratories (I) Pvt. Ltd.</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400709</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrabenazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

